A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Exclusion Criteria

• •Has not received prior systemic therapy for their locally advanced or metastatic NSCLC.
• •Provides a fresh tumor tissue sample obtained at the time of or after the initial diagnosis of locally advanced or metastatic NSCLC.
• •Has a PD-L1-high (Tumor cells \[TC\] ≥50%) tumor
• •Has measurable disease (at least 1 target lesion) based on RECIST 1.1
• •Has an Eastern Cooperative Oncology Group (ECOG) Performance status (PS) score of 0 or 1.
• •Has adequate organ function
• •Has NSCLC with a tumor that harbors any of the following molecular alterations:
• •1. Epidermal growth factor receptor (EGFR) mutations that are sensitive to available targeted inhibitor therapy
• •2. Anaplastic lymphoma kinase (ALK) translocations that are sensitive to available targeted inhibitor therapy
• •3. Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first line treatment of locally advanced or metastatic NSCLC.
• +13 more criteria